The Rabies Diagnostics Market is changing due to technological advances, awareness, and rising global rabies incidence.
The market is primarily affected by the growth of rabies incidence worldwide, especially in developing economies. This has increased the requirement for fast, effective diagnostics.
Rabies prevention and control awareness is crucially promoted by governments and NGOs. Thus, diagnostics demand has increased and regulatory frameworks have affected business dynamics.
Due to the emphasis on preventive measures like animal immunization, it has affected the diagnostics business. Vaccination and early rabies diagnosis work together to reduce rabies.
Global economic integration affects the rabies diagnostics business. Because worldwide trade and travel spread rabies, reliable diagnoses are essential for monitoring and control.
Intense competition among key rivals drives industry dynamics. Businesses are investing in research and development to create new diagnostic tools, creating a competitive climate that drives innovation.
Accessibility and cost-effectiveness of rabies diagnostics are key market factors. Diagnostics that are cost-effective and easy to deploy in low-resource contexts are becoming increasingly relevant.
Diagnostic tools are increasingly using AI. Artificial intelligence enhances rabies diagnosis accuracy and speed, which changes market dynamics by setting new performance standards.
Academic, public health, and diagnostic relationships have grown in recent years. These cooperation help build full diagnostic solutions and share knowledge and technologies.
Despite promising trends, factors include lack of knowledge, poor infrastructure, and long regulatory approvals are slowing industry growth. Sustainable market expansion requires overcoming these hurdles.
Continuous research, technological improvements, and joint activities will shape market dynamics. Future advances may include point-of-care diagnostics, cost reductions, and acceptability in underdeveloped nations.
Rabies Diagnostics Market OverviewÂ
Rabies Diagnostics Market Segmentation
The global rabies diagnostics market has been segmented on the basis of method, technology, end-user, and region.
On the basis of method, the market has been classified as a fluorescent antibody test (FAT), immunohistochemical test, amplification methods, histologic examination, and serology tests. Also, by technology, the market has been segmented into ELISA/immunohistochemistry, chromatography techniques, PCR, and others.
Based on market has been divided into hospitals, diagnostic centers, cancer palliative care clinics, and others. By end-user hospitals are likely to register the highest CAGR owing to the rising prevalence of rabies in emerging countries during the forecast period.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rabies diagnostics market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European rabies diagnostics market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.Â
The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.
Global Rabies Diagnostics Market Share, by Region, 2017 (%)
Source: MRFR Analysis
Asia-Pacific is likely to dominate the rabies diagnostics market during the forecast period owing to the improving healthcare infrastructure, rising investments in healthcare and expansions by market players in the region. Also, countries such as India and China are considering the fastest growing region due to a government focused toward adopting new technology and the best treatment option from a developed country. According to the World Health Organization, in 2010, the healthcare expenditure of India was 3.27% of GDP, whereas, in 2015 it has 3.89% of total GDP.
The Americas are likely to be the second-largest market in the global rabies diagnostics market owing to the rising strategic alliance by major players, increasing awareness about rabies, the involvement of non-profit organization to control rabies, and well-established healthcare infrastructure. According to the American Pet Products Association's 2017-2018 National Pet Owners Survey, Number of animals in the American region is increasing, and there were around 60.2 million dogs, and47.1pet cats were present in the Americas.Â
The European market is expected to hold a significant share in the rabies diagnostics market. The market growth in this region can be attributed to the government funding, well-established healthcare sector, and support of the healthcare sector coupled with increasing research and development.
The market in the Middle East & Africa is expected to account for the smallest share of the global rabies diagnostics market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Rabies Diagnostics Market Key Players
Some of the key players in the global market are Bio-Rad Laboratories, Inc., Merck KGaA, Aviva Systems Biology Corporation, Creative Diagnostics, Demeditec Diagnostics GmbH, Abbexa Ltd., Norgen Biotek Corp., BioNote, Inc., Express Biotech International Inc., MyBioSource.com., and BioGen Technologies
Global Rabies Diagnostics Market, by Method
Global Rabies Diagnostics Market, by Technology
Global Rabies Diagnostics Market, by End User
Global Rabies Diagnostics Market, by Region
Company Profiles
In April 2022
Cadila Pharmaceuticals announced that it had developed the world's first novel three-dose vaccine against rabies. The three-dose vaccine, named 'ThRabis,' is a recombinant nano-particle-based G protein vaccine prepared using Virus-like Particle technology.
The company added that the three-dose schedule is spread over one week.
The new vaccine will prove to be a game-changer because all the other rabies vaccines require five injections over 28 days to eliminate the threatCadila, Pharmaceuticals said at the launch ceremony of the new vaccine.
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)